Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its participation in investor conferences, including the Goldman Sachs Leveraged Finance and Credit Conference on May 12, 2022, and the Barclays High Yield Bond & Syndicated Loan Conference on May 24, 2022. Key executives such as Tom Vadaketh and Christina Cheng will represent the company. Live webcasts of these events will be accessible on the Investor Relations page of their website. Bausch Health focuses on enhancing global health through a diverse range of pharmaceutical products.
Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) reported first-quarter 2022 revenues of $1.918 billion, a 5% decrease from $2.027 billion in Q1 2021. Despite challenges, organic growth remained stable year-over-year. The company recorded a GAAP net loss of $69 million, an improvement from a $610 million loss in the same quarter last year. Adjusted EBITDA fell to $732 million, down from $852 million. Bausch + Lomb has begun trading under the 'BLCO' ticker following its IPO, which is expected to generate $630 million to reduce long-term debt. The full-year revenue guidance is set between $8.25 billion and $8.4 billion.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Thomas J. Appio as CEO and announced its leadership team and Board of Directors. Following the IPO of Bausch + Lomb, Joseph C. Papa will transition to chairman and CEO of Bausch + Lomb. The new executive team comprises experienced leaders, including Thomas Vadaketh as CFO and Seana Carson as General Counsel. Richard Mulligan, Ph.D., was appointed to the Board. The full separation of Bausch + Lomb is expected to finalize on May 10, 2022, with shares trading under the symbol 'BHC'.
Bausch + Lomb Corporation, a subsidiary of Bausch Health (NYSE/TSX: BHC), has announced the pricing of its initial public offering (IPO) of 35 million common shares at $18.00 each. Bausch + Lomb will not receive the proceeds from this offering, as it is being conducted by the Selling Shareholder. The shares are set to trade on the NYSE and TSX under the ticker symbol 'BLCO' starting May 6, 2022. Following the IPO, Bausch Health will retain around 90% of Bausch + Lomb's shares, decreasing to 88.5% if the underwriters' over-allotment option is fully exercised.
Bausch Health and Novaliq announced that their investigational treatment NOV03 successfully met primary endpoints in two pivotal Phase 3 trials for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The latest trial results demonstrated significant improvements in total corneal fluorescein staining and eye dryness scores at day 57. With potential FDA submission in Q2 2022, NOV03 could become the first pharmaceutical therapy available in the U.S. targeting this common ocular condition affecting approximately 18 million Americans.
Bausch Health Companies (NYSE/TSX: BHC) will announce its first-quarter financial results on May 10, 2022. A conference call and live webcast will be held at 8:00 a.m. ET to discuss these results and provide a business update. Investors can access materials through the Investor Relations section of the Bausch Health website before the call.
Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies (NYSE/TSX: BHC), has announced its initial public offering (IPO), offering 35 million common shares with an expected price range of $21 to $24 per share. A 30-day option for underwriters to purchase an additional 5.25 million shares is also planned. Post-IPO, Bausch Health will hold approximately 90% of Bausch + Lomb's shares. The IPO aims for listing on the NYSE and TSX under the ticker symbol 'BLCO'. Bausch + Lomb will not receive any IPO proceeds.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced an arrangement agreement to facilitate the separation of its eye health business, Bausch + Lomb Corporation. This agreement outlines terms for transferring shares of Bausch + Lomb to Bausch Health shareholders post-IPO. The arrangement is subject to various conditions, including regulatory approvals and tax opinions to ensure a tax-free transaction. A special shareholder meeting will be convened after the IPO for further consideration. Completion of the process is contingent upon meeting all aforementioned conditions.
Bausch + Lomb, a leading eye health business of Bausch Health Companies (NYSE/TSX: BHC), will showcase 13 scientific poster presentations at the ARVO annual meeting from May 1-4, 2022. Presentations will include pivotal Phase 3 trial results for NOV03, an investigational treatment for dry eye disease, and data on XIPERE® for macular edema associated with uveitis. The company emphasizes its commitment to research and innovation in ophthalmology, aiming to provide valuable insights for eye care professionals.